Presidio Pharmaceuticals, Inc. To Present Data On Their Lead Hepatitis C Virus NS5A Inhibitor Program At The EASL Conference

Main Category: Liver Disease / Hepatitis
Article Date: 19 Apr 2009 - 0:00 PDT

email to a friend   printer friendly   opinions  

Presidio Pharmaceuticals, Inc. announced that Dr. Richard Colonno, the company's Chief Scientific Officer, would be presenting data on their hepatitis C virus NS5A inhibitor program at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL) in Copenhagen, Denmark (April 22-26, 2009). Dr. Colonno will be presenting new data on several series of potent NS5A inhibitors in a poster entitled Identification and Profile of Potent and Selective Inhibitors of HCV NS5A Protein - Poster #875, Saturday April 25, 2009.

The full abstract is now available for viewing on http://www.easl.ch.

About Presidio Pharmaceuticals, Inc.

Presidio Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the in-licensing, development and commercialization of novel therapeutics for viral infections, including HCV and HIV-1. Presidio has raised over $27 million in financing from Panorama Capital, Baker Brothers Investments, Bay City Capital, Ventures West, Nexus Medical Partners, and Sagamore Bioventures LLC. For more information, please visit our website at http://www.presidiopharma.com.

Source
Presidio Pharmaceuticals, Inc

• Additional
• References
• Citations